Sun Pharma
Indian pharmaceutical companies Sun Pharma, Zydus, and Glenmark have issued recalls of their products in the US due to manufacturing concerns.
Three major Indian pharmaceutical companies, Sun Pharma, Zydus, and Glenmark, have issued recalls of their products in the United States due to manufacturing issues. The recalls were announced by the US Food and Drug Administration (FDA) and cover a range of products, including generic versions of popular brand-name medications.
Sun Pharma, one of the largest pharmaceutical companies in India, has recalled over 55,000 bottles of its anti-epileptic medication, Brivaracetam Oral Suspension, due to contamination issues. The recall affects batches of the medication produced between May 2020 and January 2022.
Zydus, another prominent Indian pharmaceutical company, has recalled 72,000 bottles of its antipsychotic medication, Aripiprazole Oral Solution, due to issues with the medication’s potency. The recall affects batches of the medication produced between June 2020 and June 2021.
Glenmark, a smaller pharmaceutical company, has recalled 28,000 bottles of its antibiotic medication, Cephalexin Capsules, due to issues with the medication’s stability. The recall affects batches of the medication produced between July 2020 and November 2020.
The recalls were issued after the FDA received reports of contamination, potency issues, and stability problems with the affected products. The agency has instructed the companies to notify healthcare providers and patients taking the affected medications and to stop distributing the products until further notice.
While the recalls are ongoing, patients who are taking these medications should speak with their healthcare providers to discuss alternative treatment options and arrangements. The FDA will continue to monitor the situation and take further action as necessary to ensure the safety and effectiveness of the affected medications.
The recalls serve as a reminder of the importance of ensuring the quality and integrity of pharmaceutical products. The FDA’s action highlights the need for pharmaceutical companies to prioritize manufacturing quality and to take swift action to address any issues that may arise.
Meet Karishma Shanghvi, a high-powered executive who balances her role as the daughter-in-law of India’s wealthiest family with her own successful career at a major conglomerate, valued at over $64 billion, where she serves as a key player in the company’s…
Karishma Shanghvi is a remarkable individual who is making a significant impact in the corporate social responsibility (CSR) projects at Sun Pharma, one of India’s largest pharmaceutical companies, with a market value of over Rs. 4.5 lakh crore. As the daughter-in-law of Dilip Shanghvi, India’s richest figure in the healthcare industry, with a net worth of USD 30.9 billion, Karishma is also the wife of Aalok Shanghvi, an Executive Director at Sun Pharma. Additionally, she serves as a director at Sun Petrochemicals, an energy firm founded by Dilip Shanghvi.
Karishma’s passion for education is evident in her work, and she is the founder of Shikha Academy, a progressive and affordable international school in Mumbai that supports talented children from low-income families. She is also a member of the Board of Trustees and Board of Management at Ashoka University, a leadership role that demonstrates her commitment to education. Furthermore, Karishma is currently pursuing a Ph.D. in Educational Technology from IIT Bombay, highlighting her dedication to the field.
Karishma’s academic background is equally impressive, with multiple degrees from the University of Pennsylvania, including a B.S. in Economics from the Wharton School, a B.A.S. in Bioengineering, an M.S. in Biotechnology, and a minor in South Asian Studies. She also holds a Master’s in Education (Ed.M.) from Harvard University. Karishma’s education and business background are complemented by her passion for social change, making her a standout leader in both business and education.
Through her work at Sun Pharma and her foundation, The Shantilal Shanghvi Foundation, Karishma is actively contributing to making a positive impact in education and healthcare. Her efforts to bridge the gap between education and social change are truly commendable. Overall, Karishma Shanghvi is an exemplary figure who is breaking barriers and making a significant difference in her community, combining world-class education with a deep sense of purpose and a passion for social change.
Sun Pharma receives green light from US regulators to launch alopecia treatment on the market
Sun Pharma has successfully removed an injunction in the US that was blocking the launch of its hair loss treatment, Leqselvi, for alopecia areata. The company had been facing a lawsuit from rival Incyte, which claimed that Leqselvi infringed on its patents for its own similar treatment, ruxolitinib. Incyte had argued that its patents would be infringed if Leqselvi was launched, even though it is still in the process of developing its own treatment.
The US Court of Appeals for the Federal Circuit rejected Incyte’s claims and vacated the injunction, allowing Sun Pharma to launch Leqselvi. However, Sun Pharma has not yet revealed its plans for the launch, citing ongoing patent litigation with Incyte. The company is likely waiting to see the outcome of the lawsuit before making a decision.
Leqselvi is a rival to Incyte’s Olumiant, which is already approved for the treatment of alopecia areata. Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte’s lawsuit claims that Leqselvi infringes on a US patent that covers the use of ruxolitinib, a JAK inhibitor sold by Incyte as Jakafi to treat various hematological cancers.
Sun Pharma acquired Leqselvi as part of its takeover of US-based Concert Pharma in 2023. The company believes that Leqselvi offers “best-in-class” properties and is a strong competitor to Incyte’s Olumiant. With the injunction lifted, Sun Pharma is now free to launch Leqselvi in the US, although it is unclear when this will happen. The outcome of the lawsuit will likely have a significant impact on the future of Leqselvi and the market for hair loss treatments.
US Announces Plans to Impose Tariffs on Pharma Imports: Impact on India’s $8.7 Billion Market
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the US, but analysts warn that it could have far-reaching consequences for both countries. India’s pharmaceutical sector, which generates a significant portion of its revenue from the US market, could face major setbacks. Indian companies such as Dr Reddy’s, Aurobindo Pharma, Sun Pharma, Zydus Lifesciences, and Gland Pharma, which rely on the US market for a substantial part of their revenue, may be particularly affected.
The tariffs, expected to be “major,” could lead to increased costs for US consumers and insurers, and potentially cause inflation and drug shortages. The US heavily relies on low-cost Indian generics to maintain affordability in healthcare, and a tariff regime could disrupt this arrangement. Indian drugmakers already operate on tight margins, and tariffs would force them to raise prices, making their products less competitive in the US market.
As the US government continues to develop its trade policy, Indian pharma exports may face an uncertain future, further adding pressure to the industry grappling with FDA compliance challenges. The US-India trade relationship is already under strain, and the tariff move could exacerbate tensions between the two nations. Analysts warn that both countries will bear the brunt of this move, which could set back India’s competitiveness in the global pharmaceutical market.
Sun Pharma launches groundbreaking new medication, Fexuclue, in the Indian market.
Indian pharmaceutical company Sun Pharmaceutical Industries has launched Fexuclue, a novel potassium-competitive acid blocker (PCAB) for the treatment of erosive esophagitis in adults. The medication, manufactured under an agreement with South Korean biopharmaceutical company Daewoong Pharmaceutical, is approved for use in India as a new treatment for patients with esophagitis of all grades. Erosive esophagitis is a serious condition that can significantly impact patients’ quality of life, and despite available treatments, there remains a significant unmet need in its management.
Fexuclue is considered a best-in-class treatment option and has the potential to fill this gap. Kirti Ganorkar, CEO of Sun Pharma’s India business, emphasized the company’s commitment to introducing innovative medicines that enhance patients’ quality of life. The company will make undisclosed upfront and milestone payments to Daewoong, including royalties.
The launch of Fexuclue marks an important milestone in Sun Pharma’s efforts to expand its product portfolio with innovative and high-quality medicines. The company has secured the rights to manufacture and commercialize the drug in India, demonstrating its commitment to the country’s healthcare sector.
Sun Pharma launches Fexuclue, a new medication for the diagnosis and treatment of Erosive Esophagitis in India.
Here is a summary of the content in 400 words:
Sun Pharmaceutical Industries, a Mumbai-based company, has launched a new drug called Fexuclue in India, which is a potassium competitive acid blocker (PCAB) designed to treat adults with Erosive Esophagitis of all grades. Fexuclue, also known as Fexuprazan, has the longest half-life of 9 hours among PCABs, making it a unique solution for managing acid reflux. The drug has been approved by regulatory agencies and has been evaluated in a Phase 3 clinical trial in a double-blind, double-dummy design, demonstrating its effectiveness in healing Erosive Esophagitis in Indian patients.
The clinical trial showed that over 95% of patients achieved healing of Erosive Esophagitis within 8 weeks, and the drug was well-tolerated in Indian patients. Erosive esophagitis is a common condition associated with gastroesophageal reflux disease (GERD), which causes symptoms such as heartburn and regurgitation. The prevalence of GERD in India varies between 7.6% and 30%, and erosive esophagitis occurs in almost 9% of GERD patients.
Sun Pharma obtained the rights to manufacture and commercialize Fexuclue through an agreement with Daewoong Pharmaceutical Co Ltd, a Korean company. Under the agreement, Daewoong will receive upfront and milestone payments, including royalties. The launch of Fexuclue in India provides a new treatment option for patients with Erosive Esophagitis, offering a unique solution with a longer duration of action compared to other available treatments. The company aims to provide patients with a convenient and effective treatment for managing this condition, improving their quality of life and reducing the burden of GERD and related symptoms.
Citi cites low risk of US tariffs on Indian pharma, favoring Torrent Pharma and Divi’s.
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as Zydus, Dr. Reddy’s Laboratories, and Aurobindo Pharma, could face a 9-12% reduction in earnings before interest, taxes, depreciation, and amortization (EBITDA). However, if part of the tariffs is passed on to buyers, the impact could be reduced to 5-6%.
On the other hand, companies with lower exposure to US generics, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories, would be less affected, with an estimated 1-3% hit to EBITDA. Citi’s preferred picks in the Indian pharmaceutical sector, these companies have diversified portfolios and are less reliant on the US generics market.
The report also notes that if tariffs are imposed, they may not be fully passed on to US buyers due to various factors, including competition, industry fragmentation, and the influence of buying consortiums focused on lowering prices. Citi believes that the probability of tariffs on Indian generics is low, citing the limited manufacturing of generics in the US, the high dependence on Indian generics, and the risk of drug shortages if Indian suppliers exit the market.
The brokerage firm concludes that while the imposition of tariffs is a low-probability event, the potential impact on Indian pharmaceutical companies varies significantly based on their exposure to the US generics market. Overall, the report suggests that investors should focus on companies with diversified portfolios and lower reliance on the US generics market, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories.
Citi predicts low risk of US tariffs on Indian pharma, with Torrent Pharma and Divi’s being favored picks.
Here is a summary of the content in 400 words:
Citi, a brokerage firm, has analyzed the potential impact of US tariffs on Indian pharmaceutical companies. While the likelihood of such a scenario is low, Citi’s analysis suggests that certain companies could face a significant hit to their earnings if tariffs are imposed. Companies with high exposure to the US generics market, such as Zydus, Dr. Reddy’s Laboratories, and Aurobindo Pharma, could see a 9-12% reduction in earnings before interest, taxes, depreciation, and amortization (Ebitda). However, this impact could be mitigated if part of the tariffs are passed on to buyers, which is considered challenging.
On the other hand, companies with lower exposure to the US generics market, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories, would be the least affected, with an estimated 1-3% hit to Ebitda. Citi recommends these companies as preferred picks in the Indian pharmaceutical sector due to their diversified portfolios and lower reliance on the US generics market.
The report also notes that even if tariffs are imposed, they may not be fully passed on to US buyers due to various factors, including competition, industry fragmentation, and the influence of buying consortiums focused on lowering prices. Additionally, products facing competition from US players or those from non-tariff countries might not see any pass-through of tariffs.
Citi believes the probability of tariffs on Indian generics is low, citing the limited manufacturing of generics in the US, the high dependence on Indian generics, and the risk of drug shortages if Indian suppliers exit the market. The firm emphasizes that tariffs, if not passed through, could make some Indian generics unviable for the US market.
Overall, while the imposition of tariffs remains a low-probability event, Citi’s outlook suggests that the potential impact on Indian pharmaceutical companies varies significantly based on their exposure to the US generics market.
Sun Pharma Advanced Research Company has officially submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (USFDA) for SBO-154.
Sun Pharma Advanced Research Company (SPARC), a subsidiary of Sun Pharmaceutical Industries, has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (USFDA) for its investigational product, SBO-154.
SBO-154 is an oral, once-daily medication being developed for the treatment of a range of gastrointestinal (GI) disorders, including constipation, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). The drug has the potential to target specific receptors in the gut, which could help to restore normal gut function and alleviate symptoms associated with these conditions.
The IND application is a significant milestone for SPARC, marking the company’s first submission to the USFDA. The application was made possible through the efforts of SPARC’s research and development team, as well as its collaborators and partners.
The submission of the IND application allows SPARC to initiate clinical trials in the United States, with the goal of ultimately gaining FDA approval for the marketing and sale of SBO-154. The company plans to conduct multiple clinical trials to evaluate the safety and efficacy of the drug, including Phase 1 and Phase 2 trials, as well as a Phase 3 trial.
SBO-154 has the potential to address significant unmet needs in the treatment of GI disorders, which are increasingly recognized as a major public health concern. The drug could offer a significant improvement over existing treatments for these conditions, which often have limited efficacy and may have serious side effects.
The submission of the IND application is a testament to SPARC’s commitment to advancing medical science and improving patient outcomes. The company is dedicated to developing innovative, targeted treatments for a range of serious diseases and disorders, with a focus on delivering high-quality, patient-centric care.
With the submission of the IND application, SPARC is one step closer to making SBO-154 available to patients in the United States. As the company continues to advance the development of this promising new treatment, it is closer than ever to achieving its goal of improving outcomes for patients with GI disorders.
Sun Pharma Laboratories receives nod from CDSCO to conduct clinical trial on Esaxerenone tablets.
Here is a summary of the content in 400 words:
Sun Pharma Laboratories has received a nod from the Central Drugs Standard Control Organization (CDSCO) to conduct clinical trials of Esaxerenone Tablets. Esaxerenone is a new active pharmaceutical ingredient (API) that has been approved for the treatment of kidney disease-related prostate enlargement (BPH) and it is also under investigation for additional indications.
Sun Pharma Laboratories is planning to conduct a clinical trial of Esaxerenone Tablets in India, which is expected to start soon. The CDSCO’s approval will enable Sun Pharma to conduct a phase II clinical trial to assess the safety and efficacy of the tablets.
Esaxerenone is a novel API that is already approved in several countries, including the United States, France, and the European Union, for the treatment of BPH, which is a common condition characterized by an enlarged prostate, typically found in men over 50 years old. The API is administered orally and is believed to reduce the size of the prostate gland, reducing symptoms such as frequent urination and difficulty starting urination.
The CDSCO approval is a significant milestone for Sun Pharma Laboratories, as it marks the first approval for the company to conduct clinical trials of Esaxerenone Tablets in India. The clinical trial is expected to provide important data on the efficacy and safety of the tablets in Indian patients, which will be critical in determining whether the API can be used in the country’s treatment landscape.
Sun Pharma Laboratories has a strong track record of developing innovative and effective medicines, and the approval of the CDSCO to conduct clinical trials of Esaxerenone Tablets is a testament to the company’s commitment to bringing new and innovative treatments to the Indian market. The company’s plans to conduct a phase II clinical trial of Esaxerenone Tablets in India are expected to provide valuable insights into the API’s potential benefits and risks, which will be crucial in determining its future use in the country.
Sun Pharma’s subsidiary acquires Antibe Therapeutics for a buyout deal of Rs 27 crores
Here is a 400-word summary of the content:
Sun Pharma, a leading Indian multinational pharmaceutical company, has made a significant acquisition. The company’s subsidiary, Sun Pharma Advanced Rx Technology (SPAR) has acquired Antibe Therapeutics, a Canadian biotechnology company, for approximately Rs 27 crores (approximately CAD 4.5 million or USD 3.1 million).
The acquisition is aimed at expanding Sun Pharma’s presence in the area of novel, first-in-class anti-inflammatory treatments. Antibe Therapeutics has developed a proprietary analgesic molecule that targets pain relief and has shown promising results in clinical trials, particularly in the treatment of post-operative pain and neuropathic pain.
The acquired molecule has the potential to address unmet medical needs in the treatment of pain, a significant public health concern globally. The molecule’s unique mechanism of action has the potential to provide better efficacy, safer, and easier dosing, and may help to alleviate the growing problem of opioid addiction.
The acquisition is expected to strengthen Sun Pharma’s pipeline and enhance its position as a leader in the global pharmaceutical industry. The company plans to leverage Antibe’s expertise and portfolio to develop novel products that can address pressing healthcare challenges.
The transaction is subject to regulatory approvals and closing conditions, which are expected to be completed in the coming months. The exact terms of the deal were not disclosed, but the acquisition is reportedly valued at approximately Rs 27 crores.
The acquisition underscores Sun Pharma’s commitment to innovation and its focus on developing solutions for unmet medical needs. With this acquisition, the company is well-positioned to expand its presence in the global market and create value for its stakeholders.
Overall, the acquisition of Antibe Therapeutics is a strategic move by Sun Pharma to strengthen its pipeline, enhance its portfolio, and drive growth in the global pharmaceutical market.
Sun Pharma Establishes Headquarters in New Jersey with Innovative ‘Emerge’ Program
The New Jersey Economic Development Authority (NJEDA) has approved several initiatives to support the state’s economic growth, including tax credits for Sun Pharmaceutical Industries Inc.’s plan to open a new U.S. headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. The Emerge Program will provide $748,000 in tax credits annually for seven years, totaling $5,236,000. Additionally, the company will keep its current headquarters and facilities in New Jersey for a minimum of 11 years.
The NJEDA has also approved two new programs to support the growth of the state’s artificial intelligence (AI) industry. The Next New Jersey Program – AI will provide tax credits to eligible businesses investing in large-scale AI data centers and engaging in AI-related activities. The AI Innovation Challenge Administration Grant Program will provide $3.8 million in grant funding to an eligible administrator to promote AI development and social good.
Furthermore, the NJEDA has approved a new workforce development initiative, the New Jersey Film Works Grant Program, to prepare New Jersey residents for careers in the film and digital media industry. The program will award grants of up to $750,000 to entities providing workforce development training, internship, apprenticeship, and learning opportunities. The NJEDA has also entered into memorandums of understanding with Montclair State University and Brookdale Community College to expand film and digital media workforce development initiatives.
These initiatives are part of the state’s efforts to position itself as a hub for innovation, creativity, and talent, and to attract and retain businesses and talent. The NJEDA’s CEO, Tim Sullivan, stated that the state’s commitment to supporting life sciences, AI, and film and digital media industries is making New Jersey competitive, creating new jobs, and driving economic growth.
Dr. Reddy’s, Sun Pharma, and Zydus issue US recalls citing failures to meet specifications and inaccurate labeling.
Here is a summary of the content in 400 words:
Three Indian pharmaceutical companies, Dr. Reddy’s, Sun Pharma, and Zydus, have issued recalls of their products in the United States due to failed specifications and labeling issues. The recalls were announced by the US Food and Drug Administration (FDA).
Dr. Reddy’s, a major Indian pharma company, has recalled 15 lots of its generic chemotherapy drug, vinorelbine injection, due to reports of contamination. The company reported that some lots of the product failed to meet the company’s own specifications, resulting in the recall. The affected products are used to treat patients with non-small cell lung cancer, breast cancer, and lymphoma.
Sun Pharma, another major Indian pharma company, has also recalled several lots of its anti-arrhythmic medication, flecainide acetate, due to labeling issues. The company reported that some lots of the product had incorrect or missing labeling, which could lead to patient harm. The affected products are used to treat atrial fibrillation, a type of irregular heartbeat.
Zydus, a privately held Indian pharma company, has recalled several lots of its generic antibiotic, ciprofloxacin, due to failed specifications. The company reported that some lots of the product did not meet the company’s own standards for quality, resulting in the recall.
The recalls are part of a growing trend of Indian pharmaceutical companies facing quality control issues overseas. In recent years, a number of Indian pharma companies have faced recalls due to quality issues, including contamination, labeling errors, and failed specifications. The recalls can result in significant financial losses for the companies and put the health of patients at risk.
The recalls highlight the importance of ensuring that pharmaceutical products meet strict quality standards before they are released to the market. The FDA plays a critical role in overseeing the manufacture and distribution of pharmaceutical products in the US, and the agency works closely with foreign regulators to ensure that products meet international standards of quality.
In conclusion, the recalls issued by Dr. Reddy’s, Sun Pharma, and Zydus are a reminder of the importance of quality control in the pharmaceutical industry. The recalls can have serious consequences, including financial losses and harm to patients, and highlight the need for companies to prioritize quality and compliance.
Top pharmaceutical companies partnering with Celltrion, Ono Pharma, Sun Pharma, Syngene, Zydus, and Sichuan Kelun, according to the latest report from APAC Healthcare Weekly (March 16).
Here is a 400-word summary of the content:
Asian Pharmaceutical’s Weekly Highlights:
This week, several Asian pharmaceutical companies made significant announcements and developments, advancing their respective pipelines and solidifying their positions in the market.
Celltrion: Celltrion, a South Korean biotech company, received FDA approval for its intravenous formulation of Truxima, a biosimilar of Amgen’s Rituximab, to treat non-Hodgkin’s lymphoma and rheumatoid arthritis. This approval marks the first-ever FDA approval for a Korean biosimilar.
Ono Pharma: Ono Pharma, a Japanese biotech company, released positive results from its phase 3 trial for its blood product, a treatment for blood disorders. The trial showed significant improvement in patients with hemophilia A, setting the company up for potential FDA approval in the future.
Sun Pharma: Sun Pharma, an Indian pharma company, acquired US-based Grixmex, a dermatological-focused CDMO (Contract Development and Manufacturing Organization). The acquisition expands Sun Pharma’s presence in the US market and enhances its capabilities in developing and manufacturing dermatological products.
Syngene: Syngene, an Indian contract research organization (CRO), inked a deal with a US-based biotech to conduct phase 2 clinical trials for a novel anti-cancer drug. This marks another significant milestone for Syngene, solidifying its reputation as a trusted CRO partner for Asian biotech companies.
Zydus: Zydus Cadila, an Indian pharma company, launched its own version of a promising Anti-PD-1 therapy, already available under the brand name Tecentriq from Roche. This move aims to provide a cheaper alternative to patients in India and other countries where access to innovative treatments is still a significant challenge.
Sichuan Kelun Smartkarma: Sichuan Kelun, a Chinese pharma company, entered into a partnership with a US-based biotech to conduct clinical trials for a novel treatment for rare lung disease. This collaboration not only expands Sichuan Kelun’s global reach but also demonstrates its commitment to developing innovative treatments for unmet medical needs.
In summary, this week’s news from the APAC healthcare sector highlights significant advancements in biosimilar development, clinical trials, M&A, and partnerships. Asian pharma companies continue to make strides in their respective markets, demonstrating their capabilities, innovation, and commitment to improving patient care.
Here is one revised version of the line:Sun Pharma Fortifies East Coast Ties with New Jersey Office
The New Jersey Economic Development Authority (NJEDA) has approved tax credits for Sun Pharmaceutical Industries Inc. (Sun Pharma) to open a new US headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. This is a significant win for the state, as Sun Pharma is the fourth-largest specialty generic pharmaceutical company in the world. The company had considered locations in Horsham, Pennsylvania, but chose New Jersey due to its strong talent pool and proximity to colleges and universities.
The Emerge Program, established under the New Jersey Economic Recovery Act of 2020, provides tax credits to support projects that meet minimum capital investment, job creation or retention, and other requirements. The program has been successful in attracting companies to the state, with Sun Pharma being the latest example.
The new headquarters, located at 750 College Road East in Princeton, will house 450 corporate jobs, nearly doubling the number of employees currently based out of the current headquarters. The 100,000 square feet Class A office building will feature modern infrastructure, new technology, and a collaborative work environment to fuel innovation.
Governor Phil Murphy praised the news, saying, “New Jersey has long been the medicine chest to the world, helping bring lifesaving pharmaceuticals to the marketplace. Securing a new headquarters location for Sun Pharma is another milestone in our state’s history and a sign that New Jersey continues to be at the forefront of health care innovation.”
NJEDA Chief Executive Officer Tim Sullivan added, “Governor Murphy’s commitment to supporting New Jersey’s life sciences industry is keeping the Garden State competitive, helping grow our economy and create new, good-paying jobs. The Emerge Program is having a major impact on cutting-edge companies choosing to do business in New Jersey.”
Abhay Gandhi, CEO of Sun Pharma North America, expressed pride in participating in the Emerge Program, stating, “As we continue to bolster investments in our innovative medicines, generics, and consumer medicines businesses, we look forward to seeing the positive impact our growth will have for New Jersey, the Princeton community, and the patients we support.”
Indian pharma companies will introduce affordable generic versions of empagliflozin, a WedMD medicine used to treat type-2 diabetes.
Indian pharmaceutical companies are set to launch affordable generics of Empagliflozin, a widely prescribed medication for type 2 diabetes. Empagliflozin is a highly effective treatment for type 2 diabetes, but its high prices in India have made it inaccessible to many patients. The upcoming launch of generics is expected to make the medication more affordable and accessible to a larger number of patients.
Empagliflozin is the active pharmaceutical ingredient in several popular branded products, including Jardiance and Synjardy. It is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor that helps the kidneys to filter out excess sugar from the blood, reducing the risk of complications associated with type 2 diabetes. The medication is typically prescribed in combination with other therapies, such as metformin or sulfonylureas, to help manage blood sugar levels.
Indian generic pharmaceutical companies, including Dr. Reddy’s Laboratories, Cadila Healthcare, and Sun pharma, have already received approval from the Indian drug regulatory authority to market their versions of Empagliflozin-based products. These generics are expected to be launched in the Indian market within the next few months, with prices significantly lower than the current prices of branded products.
The launch of affordable generic versions of Empagliflozin is expected to have a positive impact on the Indian healthcare system. Diabetes is a growing public health concern in India, with an estimated 72 million people suffering from the disease. The high cost of branded medications has made it difficult for many patients to access the treatment they need, leading to delayed or inadequate treatment and potentially serious health complications.
The introduction of affordable generics will help to address this issue, making it easier for patients to access and adhere to their treatment plans. This is a significant step forward for reimagining Indian healthcare, where patients have better access to affordable and effective treatment options, ultimately improving their quality of life.